Eli Lilly’s experimental obesity pill, orforglipron, met its main goals in a closely watched late-stage trial, boosting the company’s standing in the fast-growing market for weight loss and diabetes treatments. The results, announced Thursday, show the pill could offer a compelling, needle-free alternative to popular injections, potentially reshaping how millions…
The European Central Bank on Thursday reduced its key interest rate by 25 basis points, citing easing inflation and…
The International Monetary Fund (IMF) will lower its global growth predictions due to rising trade tensions and market volatility,…
Globalization has long been regarded as an unstoppable wave in the world of international trade and cooperation, promoting economic…
The Organization of the Petroleum Exporting Countries announced on Wednesday that it has received revised plans from member countries…
Brazil’s government has flagged rising risks tied to public debt renegotiation, with a record level projected for 2025 as…
Lyft is positioning itself for a larger role in the global rideshare market, even as analysts remain divided on…
The DAX Index has bounced back in the past few weeks as concerns about the ongoing trade conflict between…
Japan navigated another year of overall trade deficits, but a ballooning surplus with the United States has emerged as…